|
RO120148B1
(ro)
*
|
1997-03-14 |
2005-09-30 |
Idec Pharmaceuticals Corporation |
Sistem vector şi procedeu de inserţie a unui fragment adn, în genomul celulelor de mamifere
|
|
US5830698A
(en)
*
|
1997-03-14 |
1998-11-03 |
Idec Pharmaceuticals Corporation |
Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
|
|
IL136574A0
(en)
|
1997-12-08 |
2001-06-14 |
California Inst Of Techn |
A method for forming a polynucleotide of desired properties
|
|
EP1141314A2
(en)
|
1998-12-31 |
2001-10-10 |
Chiron Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|
|
AU2221600A
(en)
|
1998-12-31 |
2000-07-31 |
Chiron Corporation |
Improved expression of hiv polypeptides and production of virus-like particles
|
|
GB9912965D0
(en)
*
|
1999-06-03 |
1999-08-04 |
Oxford Biomedica Ltd |
In vivo selection method
|
|
EP1228237A1
(en)
*
|
1999-11-01 |
2002-08-07 |
Chiron Corporation |
Expression vectors, transfection systems, and method of use thereof
|
|
DK1297170T3
(en)
*
|
2000-06-23 |
2016-03-14 |
Novozymes As |
A process for stable chromosomal integration of multiple copies of the genes
|
|
AU2002320314A1
(en)
|
2001-07-05 |
2003-01-21 |
Chiron, Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|
|
US20030170614A1
(en)
|
2001-08-31 |
2003-09-11 |
Megede Jan Zur |
Polynucleotides encoding antigenic HIV type B polypeptides, polypeptides and uses thereof
|
|
ATE420964T1
(de)
|
2001-11-16 |
2009-01-15 |
Biogen Idec Inc |
Polycistronische expression von antikörpern in cho zellen
|
|
US7164056B2
(en)
*
|
2002-05-03 |
2007-01-16 |
Pioneer Hi-Bred International, Inc. |
Gene targeting using replicating DNA molecules
|
|
NZ537277A
(en)
|
2002-07-18 |
2008-04-30 |
Crucell Holland Bv |
Recombinant production of mixtures of antibodies
|
|
USRE47770E1
(en)
|
2002-07-18 |
2019-12-17 |
Merus N.V. |
Recombinant production of mixtures of antibodies
|
|
US20040170614A1
(en)
*
|
2002-10-30 |
2004-09-02 |
Gail Bishop |
Somatic cell gene targeting vectors and methods of use thereof
|
|
EA013225B1
(ru)
|
2003-01-07 |
2010-04-30 |
Симфоген А/С |
Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток
|
|
US9856484B2
(en)
*
|
2003-01-31 |
2018-01-02 |
Bayer Cropscience N.V. |
Plant transformation with in vivo assembly of a trait
|
|
DE10303937A1
(de)
*
|
2003-01-31 |
2004-08-12 |
Icon Genetics Ag |
Pflanzentransformation mit Assemblierung einer gewünschten Sequenz in Vivo
|
|
PL1606409T3
(pl)
|
2003-03-19 |
2011-02-28 |
Biogen Ma Inc |
Białko wiążące receptor Nogo
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
KR101351122B1
(ko)
*
|
2003-05-09 |
2014-01-14 |
듀크 유니버시티 |
Ｃｄ２０-특이적 항체 및 이를 이용한 방법
|
|
WO2004106375A1
(en)
|
2003-05-30 |
2004-12-09 |
Merus Biopharmaceuticals B.V. I.O. |
Fab library for the preparation of anti vegf and anti rabies virus fabs
|
|
US20100069614A1
(en)
|
2008-06-27 |
2010-03-18 |
Merus B.V. |
Antibody producing non-human mammals
|
|
US7700097B2
(en)
*
|
2003-06-27 |
2010-04-20 |
Biogen Idec Ma Inc. |
Purification and preferential synthesis of binding molecules
|
|
ES2374526T3
(es)
|
2003-09-04 |
2012-02-17 |
Medarex, Inc. |
Vector de expresión.
|
|
US7344753B2
(en)
*
|
2003-09-19 |
2008-03-18 |
The Board Of Trustees Of The University Of Illinois |
Nanostructures including a metal
|
|
US8030833B2
(en)
*
|
2003-09-19 |
2011-10-04 |
The Board Of Trustees Of The University Of Illinois |
Electron emission device incorporating free standing monocrystalline nanowires
|
|
US7935862B2
(en)
*
|
2003-12-02 |
2011-05-03 |
Syngenta Participations Ag |
Targeted integration and stacking of DNA through homologous recombination
|
|
EP1737971B1
(en)
|
2004-01-20 |
2017-08-16 |
Merus N.V. |
Mixtures of binding proteins
|
|
PT1776136E
(pt)
|
2004-06-24 |
2012-12-05 |
Biogen Idec Inc |
Tratamento de estados que envolvem desmielinização
|
|
ES2332524T3
(es)
|
2004-07-20 |
2010-02-08 |
Symphogen A/S |
Un procedimiento para la caracterizacion de una linea celular policlonal.
|
|
EP1789070B1
(en)
|
2004-08-03 |
2012-10-24 |
Biogen Idec MA Inc. |
Taj in neuronal function
|
|
FR2879204B1
(fr)
*
|
2004-12-15 |
2007-02-16 |
Lab Francais Du Fractionnement |
Anticorps cytotoxique dirige contre les proliferations hematopoietiques lymphoides de type b.
|
|
CA2593212A1
(en)
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
Cripto binding molecules
|
|
CN100381573C
(zh)
*
|
2005-04-14 |
2008-04-16 |
北京天广实生物技术有限公司 |
快速构建目标基因高表达的哺乳动物细胞株的体系和方法
|
|
SI1904104T1
(sl)
|
2005-07-08 |
2013-12-31 |
Biogen Idec Ma Inc. |
Protitelesa SP35 in njihova uporaba
|
|
AU2006292827B2
(en)
*
|
2005-08-09 |
2013-02-14 |
Revivicor, Inc. |
Transgenic ungulates expressing CTLA4-IG and uses thereof
|
|
EP1959979A4
(en)
|
2005-11-04 |
2010-01-27 |
Biogen Idec Inc |
PROCESS FOR PROMOTING AXON GROWTH AND SURVIVAL OF DOPAMINERGIC NEURONS
|
|
US20070136826A1
(en)
*
|
2005-12-02 |
2007-06-14 |
Biogen Idec Inc. |
Anti-mouse CD20 antibodies and uses thereof
|
|
US20090175872A1
(en)
|
2005-12-02 |
2009-07-09 |
Biogen Idec Ma Inc. |
Treatment of Conditions Involving Demyelination
|
|
EP2526968A3
(en)
|
2006-01-27 |
2013-05-22 |
Biogen Idec MA Inc. |
Nogo receptor antagonists
|
|
HUE033325T2
(en)
|
2007-01-05 |
2017-11-28 |
Univ Zuerich |
Anti-beta-amyloid binder antibodies and their use
|
|
US8128926B2
(en)
|
2007-01-09 |
2012-03-06 |
Biogen Idec Ma Inc. |
Sp35 antibodies and uses thereof
|
|
GEP20125693B
(en)
|
2007-01-09 |
2012-11-26 |
Biogen Idec Inc |
Sp35 antibodies and usage thereof
|
|
EA017403B1
(ru)
|
2007-02-02 |
2012-12-28 |
Байоджен Айдек Эмэй Инк. |
Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов
|
|
CA2701189C
(en)
*
|
2007-10-11 |
2017-05-16 |
Biogen Idec Ma Inc. |
Methods for treating pressure induced optic neuropathy, preventing neuronal degeneration and promoting neuronal cell survival via administration of lingo-1 antagonists and trkb agonists
|
|
WO2009061500A1
(en)
*
|
2007-11-08 |
2009-05-14 |
Biogen Idec Ma Inc. |
Use of lingo-4 antagonists in the treatment of conditions involving demyelination
|
|
KR20100103810A
(ko)
*
|
2007-12-10 |
2010-09-28 |
알리바 바이오파마수티컬스, 아이엔씨. |
동종 재조합에 의한 표적화된 영역의 순차적인 치환 방법
|
|
EP2315779A2
(en)
|
2008-07-09 |
2011-05-04 |
Biogen Idec MA Inc. |
Compositions comprising antibodies to lingo or fragments thereof
|
|
PL2346994T3
(pl)
|
2008-09-30 |
2022-04-19 |
Ablexis, Llc |
Myszy knock-in do wytwarzania chimerycznych przeciwciał
|
|
HRP20150831T1
(hr)
|
2008-12-19 |
2015-10-09 |
Biogen International Neuroscience Gmbh |
Humana anti-alfa- sinuklein auto-protutijela
|
|
CN102341411A
(zh)
|
2008-12-31 |
2012-02-01 |
比奥根艾迪克Ma公司 |
抗-淋巴细胞毒素抗体
|
|
WO2010111180A1
(en)
|
2009-03-24 |
2010-09-30 |
Teva Biopharmaceuticals Usa, Inc. |
Humanized antibodies against light and uses thereof
|
|
JP4998814B2
(ja)
|
2009-10-01 |
2012-08-15 |
Ｔｏｔｏ株式会社 |
Ｄｎａ構築物およびそれを用いた組み換えｃｈｏ細胞の製造方法
|
|
PL3248462T3
(pl)
|
2010-03-31 |
2024-07-08 |
Ablexis, Llc |
Modyfikacja myszy metodami inżynierii genetycznej w celu wytworzenia przeciwciał chimerycznych
|
|
US20130053552A1
(en)
*
|
2010-04-30 |
2013-02-28 |
Temasek Life Sciences Laboratory Limited |
Fragment switch: a reverse genetic approach
|
|
PT2591006T
(pt)
|
2010-07-09 |
2019-07-29 |
Bioverativ Therapeutics Inc |
Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas
|
|
LT2627672T
(lt)
|
2010-10-11 |
2018-12-10 |
Biogen International Neuroscience Gmbh |
Žmogaus antikūnai prieš tau baltymą
|
|
JP6092782B2
(ja)
|
2010-11-16 |
2017-03-08 |
エクセリミューン， インコーポレイテッド |
組換えタンパク質の製造方法
|
|
JP5209693B2
(ja)
*
|
2010-12-10 |
2013-06-12 |
ロンザ・バイオロジクス・ピーエルシー |
Ｃｈｏ細胞において組換えタンパク質を発現する方法
|
|
CN103380145B
(zh)
|
2010-12-17 |
2016-10-12 |
生物控股有限公司 |
人类抗-sod1抗体
|
|
PL2723379T3
(pl)
|
2011-06-23 |
2019-05-31 |
Biogen Int Neuroscience Gmbh |
Cząsteczki wiążące przeciwko alfa-synukleinie
|
|
WO2013012733A1
(en)
|
2011-07-15 |
2013-01-24 |
Biogen Idec Ma Inc. |
Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
|
|
US10745468B2
(en)
|
2011-12-22 |
2020-08-18 |
Kota Biotherapeutics, Llc |
Compositions and methods for modified B cells expressing reassigned biological agents
|
|
US8962315B2
(en)
|
2011-12-22 |
2015-02-24 |
Elwha Llc |
Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
|
|
US9175072B2
(en)
|
2011-12-22 |
2015-11-03 |
Elwha Llc |
Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen
|
|
US10233424B2
(en)
|
2011-12-22 |
2019-03-19 |
Elwha Llc |
Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin
|
|
WO2013157953A1
(en)
|
2012-04-20 |
2013-10-24 |
Merus B.V. |
Methods and means for the production of ig-like molecules
|
|
ES2683071T3
(es)
|
2012-04-25 |
2018-09-24 |
Regeneron Pharmaceuticals, Inc. |
Direccionamiento mediado por nucleasas con grandes vectores de direccionamiento
|
|
CA2871524C
(en)
|
2012-05-07 |
2021-07-27 |
Sangamo Biosciences, Inc. |
Methods and compositions for nuclease-mediated targeted integration of transgenes
|
|
US9796780B2
(en)
|
2012-05-14 |
2017-10-24 |
Biogen Ma Inc. |
LINGO-2 antagonists for treatment of conditions involving motor neurons
|
|
AU2013270683A1
(en)
|
2012-06-08 |
2014-12-11 |
Biogen Ma Inc. |
Chimeric clotting factors
|
|
MX2015004436A
(es)
|
2012-10-09 |
2015-06-24 |
Biogen Idec Inc |
Tratamientos conjuntos y usos para tratar trastornos desmielinizantes.
|
|
JP6284548B2
(ja)
|
2012-12-21 |
2018-02-28 |
バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． |
ヒト抗タウ抗体
|
|
EP3517545A1
(en)
|
2012-12-31 |
2019-07-31 |
Neurimmune Holding AG |
Recombinant human antibodies for therapy and prevention of polyomavirus-related diseases
|
|
RS61387B2
(sr)
|
2013-02-15 |
2024-06-28 |
Bioverativ Therapeutics Inc |
Gen optimizovanog faktora viii
|
|
SG11201505926VA
(en)
|
2013-03-15 |
2015-09-29 |
Biogen Ma Inc |
Factor ix polypeptide formulations
|
|
EA201691111A1
(ru)
|
2014-01-10 |
2017-01-30 |
Байоджен Ма Инк. |
Химерные белки фактора viii и их применение
|
|
US11008561B2
(en)
|
2014-06-30 |
2021-05-18 |
Bioverativ Therapeutics Inc. |
Optimized factor IX gene
|
|
EP3174898A2
(en)
|
2014-07-29 |
2017-06-07 |
Neurimmune Holding AG |
Human-derived anti-huntingtin (htt) antibodies and uses thereof
|
|
CA2960925A1
(en)
|
2014-09-30 |
2016-04-07 |
Neurimmune Holding Ag |
Human-derived anti-dipeptide repeats (dprs) antibody
|
|
MA40835A
(fr)
|
2014-10-23 |
2017-08-29 |
Biogen Ma Inc |
Anticorps anti-gpiib/iiia et leurs utilisations
|
|
MA40861A
(fr)
|
2014-10-31 |
2017-09-05 |
Biogen Ma Inc |
Anticorps anti-glycoprotéines iib/iiia
|
|
WO2016112270A1
(en)
|
2015-01-08 |
2016-07-14 |
Biogen Ma Inc. |
Lingo-1 antagonists and uses for treatment of demyelinating disorders
|
|
CN106191040B
(zh)
*
|
2015-04-30 |
2021-09-14 |
杭州菁因康生物科技有限公司 |
基因打靶方法
|
|
UA126016C2
(uk)
|
2015-08-03 |
2022-08-03 |
Біовератів Терапеутікс Інк. |
Злитий білок фактора іх
|
|
KR20180118659A
(ko)
|
2016-02-01 |
2018-10-31 |
바이오버라티브 테라퓨틱스 인크. |
최적화된 viii 인자 유전자
|
|
CN109563482A
(zh)
|
2016-06-10 |
2019-04-02 |
埃尔瓦有限公司 |
含表达异于分泌免疫球蛋白和细胞溶解功能的膜免疫球蛋白的b淋巴细胞系的组合物和方法
|
|
JP2018035137A
(ja)
|
2016-07-13 |
2018-03-08 |
マブイミューン ダイアグノスティックス エイジーＭａｂｉｍｍｕｎｅ Ｄｉａｇｎｏｓｔｉｃｓ Ａｇ |
新規な抗線維芽細胞活性化タンパク質（ｆａｐ）結合薬剤およびその使用
|
|
WO2018013714A1
(en)
|
2016-07-13 |
2018-01-18 |
Biogen Ma Inc. |
Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders
|
|
CA3044838A1
(en)
|
2016-12-02 |
2018-06-07 |
Bioverativ Therapeutics Inc. |
Methods of inducing immune tolerance to clotting factors
|
|
KR20190090827A
(ko)
|
2016-12-02 |
2019-08-02 |
바이오버라티브 테라퓨틱스 인크. |
키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법
|
|
BR112019015569A2
(pt)
|
2017-01-31 |
2020-03-17 |
Bioverativ Therapeutics Inc. |
Proteínas de fusão do fator ix e métodos para a sua produção e uso
|
|
MX2020001593A
(es)
|
2017-08-09 |
2020-07-13 |
Bioverativ Therapeutics Inc |
Moleculas de acido nucleico y usos de las mismas.
|
|
PE20210313A1
(es)
|
2018-03-28 |
2021-02-12 |
Bristol Myers Squibb Co |
Proteinas de fusion interleucina-2/receptor alfa de interleucina-2 y metodos de uso
|
|
BR112020021855A2
(pt)
|
2018-04-27 |
2021-02-23 |
Biogen Ma Inc. |
anticorpo antirrepetição de dipeptídeo (dpr) (poli-ga) derivado de humanos
|
|
KR102914074B1
(ko)
|
2018-05-18 |
2026-01-16 |
바이오버라티브 테라퓨틱스 인크. |
A형 혈우병의 치료 방법
|
|
CN112867394B9
(zh)
|
2018-06-04 |
2024-12-06 |
马萨诸塞州渤健公司 |
具有降低的效应功能的抗vla-4抗体
|
|
CN110607326B
(zh)
*
|
2018-06-15 |
2022-11-29 |
江苏省农业科学院 |
非强启动式的外源基因表达法及其在具有毒性的目标蛋白表达中的应用
|
|
JP7602454B2
(ja)
|
2018-08-09 |
2024-12-18 |
バイオベラティブ セラピューティクス インコーポレイテッド |
核酸分子及び非ウイルス遺伝子治療のためのそれらの使用
|
|
JP7549582B2
(ja)
*
|
2018-10-01 |
2024-09-11 |
ロンザ リミテッド |
予測可能かつ安定な導入遺伝子発現を有するｓｓｉ細胞および形成の方法
|
|
KR102559149B1
(ko)
|
2018-10-26 |
2023-07-24 |
에프. 호프만-라 로슈 아게 |
재조합효소 매개 카세트 교환을 이용한 다중특이적 항체 스크리닝 방법
|
|
MX2021009662A
(es)
|
2019-02-13 |
2021-09-08 |
Brigham & Womens Hospital Inc |
Anticuerpos anti-adresina de ganglios linfaticos perifericos y usos de los mismos.
|
|
JP7803014B2
(ja)
|
2019-09-30 |
2026-01-21 |
バイオベラティブ セラピューティクス インコーポレイテッド |
レンチウイルスベクター製剤
|
|
US20230220085A1
(en)
|
2020-02-28 |
2023-07-13 |
The Brigham And Women’S Hospital, Inc. |
Selective modulation of transforming growth factor beta superfamily signaling via multi-specific antibodies
|
|
JP2023537565A
(ja)
|
2020-06-24 |
2023-09-04 |
バイオベラティブ セラピューティクス インコーポレイテッド |
タンパク質を発現するように改変されたレンチウイルスベクターの調製物から遊離第ｖｉｉｉ因子を除去する方法
|
|
US20230084036A1
(en)
|
2021-08-23 |
2023-03-16 |
Bioverativ Therapeutics Inc. |
Optimized factor viii genes
|
|
AU2022334714A1
(en)
|
2021-08-23 |
2024-04-04 |
Bioverativ Therapeutics Inc. |
Closed-end dna production with inverted terminal repeat sequences
|
|
KR20240067122A
(ko)
|
2021-09-30 |
2024-05-16 |
바이오버라티브 테라퓨틱스 인크. |
감소된 면역원성을 갖는 인자 viii 폴리펩타이드를 암호화하는 핵산
|
|
KR20260113091A
(ko)
|
2023-11-15 |
2026-07-21 |
뉴리뮨 아게 |
항-트랜스티레틴 항체, 상기 항체를 포함하는 조성물 및 트랜스티레틴-매개 아밀로이드증의 치료 또는 예방 방법
|
|
WO2026136631A1
(en)
|
2024-12-19 |
2026-06-25 |
Bristol-Myers Squibb Company |
Interleukin- 10 fusion proteins and methods of use
|